CD8A and neoplasm: Subcutaneous administration of these nanovaccines in syngeneic mouse models of EG7.OVA, TC‐1, and MC38 tumors resulted in significantly improved tumor growth control.[100b] Mechanistically, the combinatorial efficacy of STING agonist and peptide antigens was associated with enhanced antigen‐specific CD8+ T cells expansion and elevated intratumoral IFN‐γ levels in peripheral blood of mice treated with cGAMP/antigen‐loaded nanovaccines.